CN107899093A - It is a kind of to be used to suppress inner airway stent of air flue inner membrance granulation tissue hyperplasia and preparation method thereof - Google Patents
It is a kind of to be used to suppress inner airway stent of air flue inner membrance granulation tissue hyperplasia and preparation method thereof Download PDFInfo
- Publication number
- CN107899093A CN107899093A CN201711264287.9A CN201711264287A CN107899093A CN 107899093 A CN107899093 A CN 107899093A CN 201711264287 A CN201711264287 A CN 201711264287A CN 107899093 A CN107899093 A CN 107899093A
- Authority
- CN
- China
- Prior art keywords
- stent
- plga
- granulation tissue
- medicine
- rapamycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020718 hyperplasia Diseases 0.000 title claims abstract description 24
- 206010063560 Excessive granulation tissue Diseases 0.000 title claims abstract description 22
- 210000001126 granulation tissue Anatomy 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 29
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 22
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960002930 sirolimus Drugs 0.000 claims abstract description 21
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 18
- 239000011248 coating agent Substances 0.000 claims abstract description 9
- 238000000576 coating method Methods 0.000 claims abstract description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 229910045601 alloy Inorganic materials 0.000 claims description 10
- 239000000956 alloy Substances 0.000 claims description 10
- 238000003618 dip coating Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 claims description 5
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000003517 fume Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 238000010171 animal model Methods 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229920000747 poly(lactic acid) Polymers 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 9
- 208000037803 restenosis Diseases 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 235000021053 average weight gain Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 201000004193 respiratory failure Diseases 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 238000011846 endoscopic investigation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000009818 secondary granulation Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
It is a kind of to be used to suppress inner airway stent of air flue inner membrance granulation tissue hyperplasia and preparation method thereof, it is characterised in that：It is soaked with stent surface coated stain by rapamycin and polylactide glycolic acid copolymer（PLGA）The medicine film layer of preparation, it is 1 that the rapamycin prepares mass ratio with PLGA:10.The medicine for suppressing air flue granulation tissue hyperplasia and pharmaceutical carrier are mixed into medicine film by the present invention, as the degraded of pharmaceutical carrier in vivo gradually discharges medicine, play the role of suppressing granulation tissue hyperplasia, hence it is evident that improve the using effect of existing airway stent.The advantages of medicine coating carrier of the present invention has the advantages that no vitro cytotoxicity, does not produce inflammatory reaction, and medicine coating blood vessel support is strong with medicine coating carrier combination power, not easily to fall off in degradation process.By the airway stent placement after medication coat in the animal model of airway constriction, it can effectively suppress the granulation tissue hyperplasia after stent is inserted.Present invention design is reasonable, and method is simple.
Description
Technical field
It is specifically a kind of to be used to suppress air flue inner membrance granulation tissue the present invention relates to the processing of inner airway stent medication coat
Inner airway stent of hyperplasia and preparation method thereof.
Background technology
Airway constriction can cause obstructive pneumonia, atelectasis and expiratory dyspnea, and severe patient can occur respiratory failure and jeopardize
Life.Airway fistula can cause obstinate pulmonary infection, and respiratory failure can occur by severe patient and threat to life.In recent years,
With the development of endoscopic technique, biocompatible materials and stent manufacturing technology, stent placement in the treatment can be obviously prolonged patient
Life span, improve expiratory dyspnea, control pulmonary infection, the more and more concerned application in relation to airway stent, can chase after earliest
Trace back to the 90's of 19th century.Simply in the past 20 years, as the continuous development and flexible branch airway mirror of material science are in clinic
Popularization, inner airway stent, which is inserted, is just really able to the extensive use in clinic.Since first inner airway stent should in clinic
With so far, although stent in itself and inserts technology and made great progress and developed, and the application of inner airway stent is
Through making thousands of good, pernicious airway disorders patient therefrom benefit.But stent insert after there are still it is such or it is such simultaneously
Send out disease.
For airway stent there are many problems, the incidence of complication is 10%~20%.At present, asked existing for airway stent
Topic, especially stent inserts rear secondary granulation tissue hyperplasia.Granulation tissue or tumor recurrence charge into stent, formed it is new narrow,
Granulation hyperplasia is occurred in stent both ends.Because tumor tissues are by stent mesh Intracavity, therefore apply high-frequency electrocoagulation, microwave local
The part interventional technique such as injection, intracavitary irradiation can solve the problems, such as restenosis；Restenosis can be also prevented with covered stnet.
The processing of granulation tissue hyperplasia after airway stent：Although the materials such as silicone and alloy have good histocompatbility,
But stent still has 5%~35% patient airway mucous membrane to be stimulated by stent and form granuloma after inserting, and can obstructing airway, make
Air flue restenosis.There are indivedual reports that granulation tissue hyperplasia all occurs after inserting metallic support.Often need to take intracavitary low coverage
From radiotherapy, high frequency galvanocautery or cold therapy.Because of the fragile stent of laser, therefore do not have to preferably.Overlay film frame can effective ground resistance
Only tumor tissues penetrate stent and enter in stent cavity.Benign airway lesions stent insert after granulation tissue hyperplasia mainly due to
Body can betide any position of stent to the overreaction of stent, granuloma.Stent inserts the hair of rear granulation tissue propagation
Whether raw, except the reaction with body has outside the Pass, also there is direct influence on the opportunity that stent is inserted to granulation propagation.General disease
When change is in inflammation proliferation period Stent Implantation, granulomatous incidence is higher；If in scar repairing phase Stent Implantation, granuloma
The chance of generation can then significantly reduce.
In conclusion can all cause different degrees of granulation tissue hyperplasia after airway stent placement, or even occur serious
The effect of hyperplasia causes air flue restenosis, the airway stent seriously affected.
The content of the invention
One kind that the purpose of the present invention is based on the prior art situation and provides is used to suppress air flue inner membrance granulation
Inner airway stent of hyperblastosis and preparation method thereof, is coated with the airway stent placement after medicine film layer in airway constriction
In animal model, it can effectively suppress the granulation tissue hyperplasia after stent is inserted.
The purpose of the present invention is what is be achieved through the following technical solutions：
A kind of inner airway stent for being used to suppress air flue inner membrance granulation tissue hyperplasia, is soaked with mould by thunder pa in stent surface coated stain
Element and Poly(D,L-lactide-co-glycolide（PLGA）The medicine film layer of preparation.
It is 1 that the rapamycin prepares mass ratio with PLGA:10.Rapamycin can play suppression air flue in air flue and glue
Fibroblast proliferation in film, reduces the effect of fibrin hyperplasia, suppresses the hyperplasia of granulation tissue with this；And PLGA can be
Slowly degrade in human body, using PLGA as carrier, slowly discharge the rapamycin in medicine film, long-term suppression airway mucus can be played
The effect of granulation tissue hyperplasia.And 1:10 mass ratio can make the good dip-coating of medicine on stent wire surface, and unlikely
Come off in occurring medicine film during support-folding.
The Poly(D,L-lactide-co-glycolide（PLGA）Specification is 75:25, Mr=10000（Molecular weight）.
The inner airway stent is Nitinol bare bracket or Nitinol overlay film frame
Inner airway stent of the present invention, preparation method comprise the following steps that：
（1）The cleaning of nick-eltitanium alloy stent：Nick-eltitanium alloy stent is placed in after soaking 2h in organic solvent dichloromethane and taken out,
The organic impurities of rack surface is removed, is placed in 2h in fume hood, it is clear to place a stent into ultrasonic wave after dichloromethane completely volatilization
Wash in device and clean 20min and remove rack surface impurity, in oven 50 °C dry it is spare；
（2）Prepare coating stent of medicine：Prepare rapamycin and PLGA mass ratioes 1:10 lotion, using 13ml dichloromethane as
Solvent is configured to 2.5%PLGA solution 13ml, accurate weighing rapamycin 0.0325g, using methanol as solvent with 0.325g PLGA
The methanol solution 7ml of rapamycin is prepared, two kinds of solution are mixed afterwards, the nick-eltitanium alloy stent cleaned is placed in solution
Dip-coating 20min, then placing a stent into 40 °C of oven for baking 4h makes solvent fully volatilize, by aforesaid operations dip-coating again
Drying is taken out after 20min, oxirane disinfection is spare after stent is pressed into bracket conveyer.
Testing result is as follows：
Infrared spectrometer detects：PLGA- rapamycin lotions are prepared, make solvent that PLGA- rapamycin medicine films be made after volatilizing
Sample.Rapamycin is detected respectively using infrared spectrometer, PLGA and PLGA- rapamycin medicine film samples, determine by detecting
PLGA is not chemically reacted with rapamycin in stent preparation process.
Scanning electron microscopic observation：Take the tracheae coating stent of medicine prepared and the drug stent being pushed out from conveyer each
One, row scanning electron microscope detects after conventional metal spraying, and observation finds the uniform dip-coating of medicine film on the surface of stent wire（Fig. 1）,
It is and only slightly uneven in backbone metal intersection medicine film coating.
The advantage of the invention is that：The fibroblast proliferation in airway mucus is can inhibit, reduces cellulose and collagen egg
White hyperplasia, suppresses the granulation tissue hyperplasia of airway mucus, substantially improves the effect of existing airway stent.
Brief description of the drawings
Fig. 1 is the film effect schematic diagram of the present invention, and a, b, c are the sem image after stent drug coating, shows medicine
The uniform dip-coating of film is on the surface of stent wire.
Embodiment
The present invention is described further below in conjunction with attached drawing embodiment：
Used laboratory apparatus and apparatus：It is electric drying oven with forced convection, electronic balance, ultrasonic cleaner, constant temperature incubator, infrared
Spectrometer, scanning electron microscope.
A kind of inner airway stent for being used to suppress air flue inner membrance granulation tissue hyperplasia, is soaked with by thunder in stent surface coated stain
Pa mycin and Poly(D,L-lactide-co-glycolide（PLGA）The medicine film layer of preparation, preparation method comprise the following steps that：
（1）The cleaning of nick-eltitanium alloy stent：Nick-eltitanium alloy stent is placed in after soaking 2h in organic solvent dichloromethane and taken out,
2h in fume hood is placed in, is placed a stent into after dichloromethane completely volatilization in ultrasonic cleaner and cleans 20min removal stents
Surface impurity, in oven 50 °C dry it is spare；
（2）Prepare coating stent of medicine：Prepare rapamycin and PLGA mass ratioes 1:10 lotion, using 13ml dichloromethane as
Solvent is configured to 2.5%PLGA solution 13ml, accurate weighing rapamycin 0.0325g, using methanol as solvent with 0.325g PLGA
The methanol solution 7ml of rapamycin is prepared, two kinds of solution are mixed afterwards, the nick-eltitanium alloy stent cleaned is placed in solution
Dip-coating 20min, then placing a stent into 40 °C of oven for baking 4h makes solvent fully volatilize, by aforesaid operations dip-coating again
Drying is taken out after 20min, oxirane disinfection is spare after stent is pressed into bracket conveyer.
Increase weight after table 1,8mm*20mm Nitinol air flue bare brackets and overlay film frame coating
Bare bracket average weight gain 0.37mg as seen from the above table（That is medicine film weight）；Overlay film frame average weight gain 1.82mg（That is medicine
Film weight）.
Claims (5)
- A kind of 1. inner airway stent for being used to suppress air flue inner membrance granulation tissue hyperplasia, it is characterised in that：In stent surface coated Dip-coating has by rapamycin and Poly(D,L-lactide-co-glycolide（PLGA）The medicine film layer of preparation.
- 2. the inner airway stent according to claim 1 for being used to suppress air flue inner membrance granulation tissue hyperplasia, it is characterised in that： It is 1 that the rapamycin prepares mass ratio with PLGA:10.
- 3. inner airway stent according to claim 1, it is characterised in that：The Poly(D,L-lactide-co-glycolide（PLGA） Specification is 75:25, Mr=10000（Molecular weight）.
- 4. inner airway stent according to claim 1, it is characterised in that：The inner airway stent for Nitinol bare bracket or Nitinol overlay film frame.
- A kind of 5. preparation method of inner airway stent described in claim 1：It is characterized in that：Comprise the following steps that：（1）The cleaning of nick-eltitanium alloy stent：Nick-eltitanium alloy stent is placed in after soaking 2h in organic solvent dichloromethane and taken out, 2h in fume hood is placed in, is placed a stent into after dichloromethane completely volatilization in ultrasonic cleaner and cleans 20min removal stents Surface impurity, in oven 50 °C dry it is spare；（2）Prepare coating stent of medicine：Prepare rapamycin and PLGA mass ratioes 1:10 lotion, using 13ml dichloromethane as Solvent is configured to 2.5%PLGA solution 13ml, accurate weighing rapamycin 0.0325g, using methanol as solvent with 0.325g PLGA The methanol solution 7ml of rapamycin is prepared, two kinds of solution are mixed afterwards, the nick-eltitanium alloy stent cleaned is placed in solution Dip-coating 20min, then placing a stent into 40 °C of oven for baking 4h makes solvent fully volatilize, by aforesaid operations dip-coating again Drying is taken out after 20min, oxirane disinfection is spare after stent is pressed into bracket conveyer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711264287.9A CN107899093A (en) | 2017-12-05 | 2017-12-05 | It is a kind of to be used to suppress inner airway stent of air flue inner membrance granulation tissue hyperplasia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711264287.9A CN107899093A (en) | 2017-12-05 | 2017-12-05 | It is a kind of to be used to suppress inner airway stent of air flue inner membrance granulation tissue hyperplasia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107899093A true CN107899093A (en) | 2018-04-13 |
Family
ID=61853978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711264287.9A Pending CN107899093A (en) | 2017-12-05 | 2017-12-05 | It is a kind of to be used to suppress inner airway stent of air flue inner membrance granulation tissue hyperplasia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107899093A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119950825A (en) * | 2025-03-13 | 2025-05-09 | 北京工业大学 | Preparation method of piezoelectric-driven adaptive drug-releasing electrospun coated tracheal stent |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140356407A1 (en) * | 2012-03-09 | 2014-12-04 | Q3 Medical Devices Limited | Biodegradable supporting device |
| CN205459229U (en) * | 2016-01-25 | 2016-08-17 | 首都医科大学附属北京天坛医院 | Drug coating metal air flue support |
| CN106924823A (en) * | 2015-12-30 | 2017-07-07 | 上海微创医疗器械（集团）有限公司 | A kind of drug stent and preparation method thereof |
-
2017
- 2017-12-05 CN CN201711264287.9A patent/CN107899093A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140356407A1 (en) * | 2012-03-09 | 2014-12-04 | Q3 Medical Devices Limited | Biodegradable supporting device |
| CN106924823A (en) * | 2015-12-30 | 2017-07-07 | 上海微创医疗器械（集团）有限公司 | A kind of drug stent and preparation method thereof |
| CN205459229U (en) * | 2016-01-25 | 2016-08-17 | 首都医科大学附属北京天坛医院 | Drug coating metal air flue support |
Non-Patent Citations (3)
| Title |
|---|
| 李启民等主编: "《现代介入技术与临床诊疗应用 下》", 30 June 2017, 吉林科学技术出版社 * |
| 陈志峰: "丝裂霉素气管药物支架在抑制支架置入后再狭窄中的作用", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 马辉福等主编: "《临床影像诊断与介入治疗 下》", 30 September 2017, 吉林科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119950825A (en) * | 2025-03-13 | 2025-05-09 | 北京工业大学 | Preparation method of piezoelectric-driven adaptive drug-releasing electrospun coated tracheal stent |
| CN119950825B (en) * | 2025-03-13 | 2025-07-22 | 北京工业大学 | Preparation method of piezoelectric-driven adaptive drug-releasing electrospun coated tracheal stent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103142335B (en) | A kind of thermoplastic degradable fiber woven stent and preparation method thereof | |
| JP2010511427A (en) | Medical device containing collagen inhibitor | |
| CN102048602A (en) | Meshy degradable blood vessel stent and preparation method thereof | |
| US12151070B2 (en) | Drug eluting balloon and balloon catheter | |
| CN105412996B (en) | A kind of Biodegradable scaffold and preparation method thereof | |
| CN109985280A (en) | Drug balloon and preparation method thereof | |
| Jeong et al. | Augmented re-endothelialization and anti-inflammation of coronary drug-eluting stent by abluminal coating with magnesium hydroxide | |
| EP2111818A1 (en) | Intracoronary stent with asymmetric drug releasing controlled coating | |
| CN107427612A (en) | On-demand biodegradable medical devices | |
| CN108771573A (en) | It is a kind of can degradable absorption bracket for eluting medicament and its application | |
| CN102091355A (en) | Compound coating coronary medicament eluting stent and preparation method thereof | |
| CN104971387B (en) | A kind of method that Ultrasonic spraying mode prepares medication coat angiocarpy bracket | |
| CN104984412A (en) | Preparation method for paclitaxel coating on surface of drug balloon | |
| CN114796811A (en) | Drug coating balloon, drug balloon system and preparation method thereof | |
| CN1321705C (en) | Method for preparing multilayer medicine composite degradable biliary tract rack visible under X-ray | |
| CN108339159A (en) | Medicine coating and preparation method thereof | |
| CN107899093A (en) | It is a kind of to be used to suppress inner airway stent of air flue inner membrance granulation tissue hyperplasia and preparation method thereof | |
| RU2325193C2 (en) | Vascular stent | |
| CN109735819B (en) | Biomaterial with NO catalytic release and EPCs capture function and preparation method thereof | |
| CN108261559A (en) | Absorbable iron-based instrument | |
| CN102727944A (en) | Anti-benign and malignant biliary stricture drug eluting stent and preparation method thereof | |
| CN118418443A (en) | Preparation method of degradable tracheal stent | |
| CN111450315A (en) | A kind of anti-inflammatory hydrogel coated polypropylene patch and preparation method thereof | |
| CN117482301A (en) | A silver nanoparticle-coated stent, its preparation method and application | |
| CN115337523B (en) | Medicine saccule and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180413 |
|
| RJ01 | Rejection of invention patent application after publication |